4SC 205
Alternative Names: 4SC-205; LH-031Latest Information Update: 03 Oct 2023
Price :
$50 *
At a glance
- Originator Nycomed
- Developer 4SC; Link Health Group
- Class Antineoplastics; Small molecules
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
- Preclinical Liver cancer; Lung cancer
Most Recent Events
- 03 Oct 2023 4SC 205 is still in preclinical trials for Liver cancer and Lung cancer in China (PO) (4SC pipeline, October 2023)
- 03 Oct 2023 4SC 205 is still in phase I trials for Solid tumours and Lymphoma in China (PO) (4SC pipeline, October 2023)
- 13 Aug 2019 Phase-I clinical trials in Lymphoma (Late- stage disease) in China, Hong Kong, Macau and Taiwan (PO)